Bio Essence CORP (BIOE) — SEC Filings

Q: What are the key financial highlights for Bio Essence CORP?

Key financial highlights for Bio Essence CORP are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Bio Essence CORP?

Key executives at Bio Essence CORP are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Bio Essence CORP stock?

Risk factors for Bio Essence CORP (BIOE) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Bio Essence CORP?

Forward-looking statements and predictions from Bio Essence CORP are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Bio Essence CORP. Recent 10-Q filing on Nov 12, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Bio Essence CORP on SEC EDGAR

Overview

Bio Essence CORP (BIOE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Bio Essence Corp. (BIOE) reported a significant turnaround in its financial performance for the nine months ended September 30, 2025, narrowing its net loss from continuing operations to $132,890, a substantial improvement from the $1,538,158 loss in the same period of 2024. This improvement was dri

Sentiment Summary

Across 16 filings, the sentiment breakdown is: 14 neutral, 2 mixed. The dominant filing sentiment for Bio Essence CORP is neutral.

Filing Type Overview

Bio Essence CORP (BIOE) has filed 6 10-Q, 2 10-K, 4 10-Q/A, 1 8-K/A, 3 8-K with the SEC between Apr 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (16)

Bio Essence Narrows Losses, Boosts Revenue Amid Strategic Shift — 10-Q · Nov 12, 2025 Risk: high
Bio Essence Corp. (BIOE) reported a significant turnaround in its financial performance for the nine months ended September 30, 2025, narrowing its net loss fro
Bio Essence Swings to Profit on New Service Revenue, Assets Plummet — 10-Q · Aug 14, 2025 Risk: high
Bio Essence Corp. reported a net income of $59,864 for the three months ended June 30, 2025, a significant improvement from a net loss of $215,678 in the same p
Bio Essence Corp. Files Q1 2025 10-Q Report — 10-Q · May 15, 2025 Risk: low
Bio Essence Corp. filed its quarterly report (10-Q) for the period ending March 31, 2025. The company, incorporated in California and headquartered in Irvine, C
Bio Essence Corp. Files 2024 10-K — 10-K · Mar 28, 2025 Risk: low
Bio Essence Corp. filed its 2024 annual report (10-K) on March 28, 2025. The company, incorporated in California and headquartered in Irvine, operates in the Ph
Bio Essence Corp. Files 10-Q/A Amendment — 10-Q/A · Nov 27, 2024 Risk: low
Bio Essence Corp. filed Amendment No. 3 to its Form 10-Q/A for the quarterly period ended March 31, 2024. The company, incorporated in California, is located at
Bio Essence Corp. Files Q3 2024 10-Q Report — 10-Q · Nov 14, 2024 Risk: low
Bio Essence Corp. filed its quarterly report on Form 10-Q for the period ending September 30, 2024. The company, incorporated in California with its principal e
Bio Essence Corp. Files 10-Q/A Amendment — 10-Q/A · Oct 30, 2024 Risk: low
Bio Essence Corp. filed an amendment (No. 2) to its Form 10-Q for the quarterly period ended March 31, 2024. The company, incorporated in California with its pr
Bio Essence Corp Files 10-Q/A Amendment — 10-Q/A · Oct 7, 2024 Risk: low
Bio Essence Corp. filed an amendment (10-Q/A) on October 7, 2024, to its quarterly report for the period ended March 31, 2024. The company, incorporated in Cali
Bio Essence Corp. Files 10-Q/A Amendment — 10-Q/A · Aug 21, 2024 Risk: low
Bio Essence Corp. filed an amendment (10-Q/A) on August 21, 2024, for the quarterly period ended June 30, 2024. The company, incorporated in California with its
Bio Essence Corp. Files Q2 2024 10-Q — 10-Q · Aug 19, 2024 Risk: low
Bio Essence Corp. filed its 10-Q for the quarterly period ended June 30, 2024. The company, incorporated in California, is in the pharmaceutical preparations in
Bio Essence Corp. Files 8-K/A Amendment — 8-K/A · Aug 9, 2024 Risk: medium
Bio Essence Corp. filed an amendment (8-K/A) on August 9, 2024, to its report originally filed on August 5, 2024. This amendment pertains to changes in the regi
Bio Essence Corp. Changes Certifying Accountant — 8-K · Aug 5, 2024 Risk: low
Bio Essence Corp. has filed an 8-K report on August 5, 2024, to disclose a change in its certifying accountant. The company, incorporated in California with its
Bio Essence Corp. Relocates Principal Executive Offices — 8-K · Jun 21, 2024 Risk: low
Bio Essence Corp. announced on June 18, 2024, a change in its principal executive offices to 12 Chrysler, Unit B, Irvine, CA 92618. The company also filed a cur
Bio Essence Corp. Files Q1 2024 10-Q Report — 10-Q · May 17, 2024 Risk: low
Bio Essence Corp. filed its quarterly report on Form 10-Q for the period ended March 31, 2024. The company, incorporated in California and headquartered in Irvi
Bio Essence Corp. Files 2023 Annual Report on Form 10-K — 10-K · Apr 15, 2024 Risk: low
Bio Essence Corp (BIOE) filed a Annual Report (10-K) with the SEC on April 15, 2024. Bio Essence Corp. filed its annual report on Form 10-K for the fiscal year
Bio Essence Corp. Files 8-K for Material Agreement — 8-K · Apr 4, 2024 Risk: medium
Bio Essence Corp. filed an 8-K on April 4, 2024, to report a material definitive agreement. The filing does not provide specific details about the agreement, pa

Risk Profile

Risk Assessment: Of BIOE's 16 recent filings, 2 were flagged as high-risk, 2 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Bio Essence CORP's most recent 10-Q filing (Nov 12, 2025):

Revenue: $418,112
Net Income: $12,998
EPS: N/A
Debt-to-Equity: -0.96
Cash Position: $28,741
Operating Margin: -31.0%
Total Assets: $184,534
Total Debt: $3,286,514

Industry Context

Bio Essence Corp. operates in a competitive manufacturing services sector, likely focusing on Original Equipment Manufacturer (OEM) services. The industry is characterized by demand for specialized production capabilities and cost efficiency. Companies in this space often navigate complex supply chains and fluctuating client needs. Recent trends may include increased outsourcing by larger firms and a focus on niche manufacturing expertise.

Top Tags

pharmaceuticals (7) · quarterly-report (6) · 10-Q (5) · amendment (5) · Health Supplements (2) · Manufacturing Services (2) · Going Concern (2) · Small Cap (2) · 10-K (2) · 10-Q/A (2)

Key Numbers

Net loss from continuing operations (9 months ended Sep 30, 2025): $132,890 — Significantly reduced from $1,538,158 in 2024
Total revenues (9 months ended Sep 30, 2025): $418,112 — Increased from $176,385 in 2024, driven by manufacturing services
Net income (3 months ended Sep 30, 2025): $12,998 — A positive shift from a $1,199,493 net loss in the prior year's quarter
Accumulated deficit (as of Sep 30, 2025): $10,582,160 — Indicates significant historical losses and contributes to going concern risk
Total Liabilities (as of Sep 30, 2025): $3,286,514 — Significantly exceeds total assets of $184,534
Total Assets (as of Sep 30, 2025): $184,534 — A decrease from $281,024 as of December 31, 2024
Increase in Customer Deposit (9 months ended Sep 30, 2025): $642,524 — A significant increase from $146,000 in 2024, indicating potential future revenue
Common shares outstanding: 38,009,000 — Consistent across periods, indicating no recent dilution from new share issuance
Net income for Q2 2025: $59,864 — Significant improvement from a $215,678 net loss in Q2 2024
Total revenues for six months ended June 30, 2025: $281,312 — Increased from $41,695 in the prior year period, driven by manufacturing services
Manufacture service revenue for six months ended June 30, 2025: $280,096 — New revenue stream, zero in prior year period
Sales of goods for six months ended June 30, 2025: $0 — Decreased from $41,695 in the prior year period
Accumulated deficit as of June 30, 2025: $10,595,158 — Indicates substantial historical losses and raises going concern doubts
Total assets as of June 30, 2025: $112,692 — Decreased significantly from $281,024 at December 31, 2024
Total Stockholders' Deficit as of June 30, 2025: $3,114,978 — Worsened from $2,969,090 at December 31, 2024

Frequently Asked Questions

What are the latest SEC filings for Bio Essence CORP (BIOE)?

Bio Essence CORP has 16 recent SEC filings from Apr 2024 to Nov 2025, including 6 10-Q, 4 10-Q/A, 3 8-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BIOE filings?

Across 16 filings, the sentiment breakdown is: 14 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Bio Essence CORP SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Bio Essence CORP (BIOE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Bio Essence CORP?

Key financial highlights from Bio Essence CORP's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for BIOE?

The investment thesis for BIOE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Bio Essence CORP?

Executive information for Bio Essence CORP is extracted from SEC filings as they are enriched with AI analysis.

What are the main risk factors for Bio Essence CORP stock?

Of BIOE's 16 assessed filings, 2 were flagged high-risk, 2 medium-risk, and 12 low-risk.

What are recent predictions and forward guidance from Bio Essence CORP?

Forward guidance and predictions for Bio Essence CORP are extracted from SEC filings as they are enriched.